Changeflow GovPing Healthcare & Life Sciences Methods and Compositions for Hematopoietic Cell...
Routine Notice Added Final

Methods and Compositions for Hematopoietic Cell Differentiation

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

USPTO published application US20260109951A1 titled "Methods and Compositions for Inducing Hematopoietic Cell Differentiation," filed September 12, 2023. The application discloses culture platforms, cell media, and methods for differentiating pluripotent stem cells into hematopoietic lineage cells including T cell progenitors, NK cells, NKT cells, and B cells. Named inventors are Alec Witty, Amanda Yzaguirre, Jode Goodridge, Bahram Valamehr, Samuel Adam LaBarge, and Sean Sherman.

“The pluripotent stem cell-derived definitive HE cells produced by methods provided herein are capable of differentiating into hematopoietic lineage cells comprising T cell progenitors and T cells, in addition to NK cell progenitors, NK cells, NKT cells, or B cells.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.

What changed

USPTO published application US20260109951A1, a patent application for methods and compositions for inducing hematopoietic cell differentiation, including culture platforms and cell media for generating pluripotent stem cell-derived definitive HE cells capable of producing T cell progenitors, NK cells, NKT cells, and B cells. The application was filed September 12, 2023, and published April 23, 2026.

For biotechnology companies and researchers in cell therapy development, this publication establishes the application as prior art as of the filing date. Any subsequent filings in this space should conduct freedom-to-operate analyses around the claimed differentiation methods and culture platforms disclosed in this application.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION

Application US20260109951A1 Kind: A1 Apr 23, 2026

Inventors

Alec WITTY, Amanda YZAGUIRRE, Jode GOODRIDGE, Bahram VALAMEHR, Samuel Adam LABARGE, Sean Sherman

Abstract

In various aspects, the invention provides culture platforms, cell media, and methods of differentiating pluripotent cells into hematopoietic cells. In certain aspects, the invention further provides pluripotent stem cell-derived hematopoietic cells generated using the culture media and methods disclosed herein. The pluripotent stem cell-derived definitive HE cells produced by methods provided herein are capable of differentiating into hematopoietic lineage cells comprising T cell progenitors and T cells, in addition to NK cell progenitors, NK cells, NKT cells, or B cells.

CPC Classifications

C12N 5/069 C07K 14/5443 C12M 47/04 C12N 5/525 C12N 2501/155 C12N 2501/727 C12N 2501/998 C12N 2506/45 C12N 2510/00

Filing Date

2023-09-12

Application No.

19111618

View original document →

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Biotechnology companies Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent filing Cell therapy development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Biotechnology Healthcare

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!